Royalty Pharma EVP sells 13,684 Class A shares
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported an open-market sale of 13,684 Class A Ordinary Shares on May 14, 2026 at a weighted average price of $53.0647 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported an open-market sale of 13,684 Class A Ordinary Shares on May 14, 2026 at a weighted average price of $53.0647 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026.
Following the sale, Urist directly holds 31,881 Class A Ordinary Shares and indirectly holds 19,020 shares through an IRA. The sale price reflected multiple transactions within a range of $52.88 to $53.25 per share.
Insider Trade Summary 10b5-1
Net Seller: 13,684 shares
Net Sell
2 txns
Insider
Urist Marshall
Role
EVP, Research & Investments
Sold
13,684 shs ($726K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Ordinary Shares | 13,684 | $53.0647 | $726K |
| holding | Class A Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Class A Ordinary Shares — 31,881 shares (Direct);
Class A Ordinary Shares — 19,020 shares (Indirect, By IRA)
Footnotes (2)
- F1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.88 to $53.25 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 13,684 shares
Weighted average sale price: $53.0647 per share
Price range: $52.88–$53.25 per share
+3 more
6 metrics
Shares sold
13,684 shares
Open-market sale on May 14, 2026
Weighted average sale price
$53.0647 per share
Class A Ordinary Shares, May 14, 2026
Price range
$52.88–$53.25 per share
Range of individual sale transactions
Direct holdings after sale
31,881 shares
Class A Ordinary Shares held directly after transaction
Indirect holdings after sale
19,020 shares
Held indirectly through IRA
Trading plan adoption date
February 12, 2026
Rule 10b5-1 plan governing reported sale
Key Terms
Rule 10b5-1 plan, weighted average price, Class A Ordinary Shares, open-market sale, +1 more
5 terms
Rule 10b5-1 plan regulatory
"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
IRA financial
"nature_of_ownership: By IRA"
An individual retirement account (IRA) is a savings account designed to help people put aside money for their retirement, often with tax advantages that encourage long-term savings. It matters to investors because it can grow over time, providing financial security later in life, and offers benefits that can reduce current taxes or allow investments to compound more effectively.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Royalty Pharma (RPRX) disclose for Marshall Urist?
Marshall Urist reported selling 13,684 Royalty Pharma Class A Ordinary Shares. The sale occurred on May 14, 2026, as an open-market transaction and was executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in February 2026.
Was Marshall Urist’s Royalty Pharma (RPRX) sale made under a Rule 10b5-1 plan?
Yes. The Form 4 states all reported transactions were effected under a Rule 10b5-1 trading plan. This plan was adopted by Marshall Urist on February 12, 2026, indicating the sale was pre-arranged rather than an ad hoc market decision.
What type of security did Marshall Urist trade in Royalty Pharma (RPRX)?
The transaction involved Royalty Pharma Class A Ordinary Shares. The Form 4 identifies the security title explicitly and reports both the number of shares sold and the resulting direct and indirect share balances after the May 14, 2026 transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
